Health: Cancer Drugs Fund

Debate between Earl Howe and Lord St John of Bletso

Wednesday 13th March 2013 Lords Chamber

[Earl Howe]

My Lords, when the arrangements for the cancer drugs fund pass to the NHS Commissioning Board in April, there will be standard operating procedures for the fund, which will provide greater consistency of access across the country while also preserving the right of clinicians to request any drug that they think will help a patient. The standard operating procedures will be published very shortly, and the noble Lord will then receive a fuller answer to his question.

[Lord St John of Bletso]

My Lords, can the Minister elaborate on what reports, if any, have been produced from the Chemotherapy Intelligence Unit in Oxford on the efficacy of the cancer drugs fund? What will be done for those patients who have received relief from this fund for their treatment in future?

[Earl Howe]

My Lords, the noble Lord raises a very important point because clinical audit of the drugs in the cancer drugs fund and their use will be extremely important in informing the use of these drugs going forward and, indeed, in determining their price under a value-based pricing scheme. As yet we have not heard from the Oxford Cancer Intelligence Unit although I understand that we will receive a preliminary report quite soon. However, as I mentioned earlier, when the current fund comes to an end we will ensure that those patients who are receiving drugs under it will continue to do so.